Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 615-240-7 | CAS number: 710292-85-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March - June 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: US EPA OPPTS 870.3650, combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
- Deviations:
- no
- Principles of method if other than guideline:
- In addition, the procedures described in this report essentially conform to the following guidelines.
1. The United States EPA Health Effects Test Guidelines, OPPTS 870.3550, Reproduction/Developmental Toxicity Screening Test, July 2000.
2. OECD Guidelines for Testing of Chemicals, Guideline 421, Reproduction/Developmental Toxicity Screening Test, July 1995.
3. Commission regulation (EC) No 440/2008 Part B: Methods for the Determination of Toxicity and other Health Effects; B.7: "Repeated Dose (28 days) Toxicity (oral)". Official Journal of the European Union No. L142, May 2008.
4. OECD Guidelines for Testing of Chemicals, Guideline 407, Repeated Dose 28-day Oral Toxicity Study in Rodents, October 2008.
5. The United States EPA Health Effects Test Guidelines, OPPTS 870.3050, Repeated dose 28-day oral toxicity study in rodents, July 2000. - GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approx. 11 weeks
- Weight at study initiation: within ± 20% of the sex mean (males: 280-309 grams, females: 191-219 grams)
- Fasting period before study: no
- Housing: groups of 5 animals/sex/cage during pre-mating and post-mating (males), females were individually housed post-mating and during lactation; Macrolon plastic cages with sterilized sawdust as bedding material and paper as cage-enrichment/nesting material
- Diet: free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany)
- Water: free access to tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18.7-20.9
- Humidity (%): 38-95; temporary deviations from the minimum and daily mean relative humidity occurred. Laboratory historical data do not indicate an effect of the deviations.
- Air changes (per hr): approx. 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: 01 May - 22 June 2012 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- Method of formulation: Formulations (w/w) were prepared daily within 6 hours prior to dosing and were homogenized to a visually acceptable level. No correction was made for the purity of the test substance. Adjustment was made for specific gravity (1.036) of the vehicle. The test substance was warmed to facilitate mixing (max temperature= 82.7°C, for a maximum of 58 minutes).
Storage conditions of formulations: at ambient temperature
Justification for use and choice of vehicle (if other than water): based on trial formulations performed at WIL Research Europe
Dose volume: 5 mL/kg body weight. Actual dose volumes were calculated according to the latest body weight
Method of gavage: using a plastic feeding tube. Formulations were placed on a magnetic stirrer during dosing. - Details on mating procedure:
- Following a minimum of 14 days of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating occurred, the males and females were separated.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chemical analysis were conducted twice during the main study (Days 2 and 14 of the treatment phase; 02 and 14 May 2012 respectively), according to a validated method (Project 498662). Samples of formulations were analyzed for homogeneity (highest and lowest concentration) and accuracy of preparation (all concentrations). Stability in the vehicle over 6 hours at room temperature was also determined (highest and lowest concentration).
The concentrations analysed in the formulations of Group 2, Group 3 and Group 4 were in agreement with target concentrations (i.e. mean accuracies between 85% and 115%).
A small response at the retention time of the test substance was observed in the chromatograms of the Group 1 formulation prepared for use on Day 14. The maximum contribution based on area to the other samples was 3.3%. A small response was also seen in the blank injection sample analyzed. In the formulations of Group 1 of Day 2, no test substance was detected.
The formulations of Group 2 and Group 4 were homogeneous (i.e. coefficient of variation ≤ 10%).
Formulations at the entire range were stable when stored at room temperature under normal laboratory light conditions for at least 6 hours (relative difference before and after storage was maximally 10%). - Duration of treatment / exposure:
- Males were exposed for 29 days, i.e. 2 weeks prior to mating, during mating, and up to termination. Females were
exposed for 42-52 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4
days of lactation. Female nos. 49 (Group 1), 54 (Group 2) and 75 (Group 4) were not dosed during littering. - Frequency of treatment:
- Once daily for 7 days per week, approximately the same time each day with a maximum of 6 hours difference between the earliest and latest dose. Animals were dosed up to the day prior to scheduled necropsy.
- Details on study schedule:
- At mating animals were at least 13 weeks old.
- Remarks:
- Doses / Concentrations:
100, 300 and 1000 mg/kg bw/d
Basis:
actual ingested - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Parturition:
The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes, placentas cleaned up, nest built up and/or feeding of pups started). Females that were littering were left undisturbed.
Identification of pups:
On Day 1 of lactation, all pups were randomized per litter and individually identified by means of subcutaneous injection of Indian ink.
Selection of animals for selected measurements:
5 animals/sex/group were randomly selected at allocation for functional observations, locomotor activity, clinical pathology, macroscopic examination (full list), organ weights (full list) and histopathology. Only females with live offspring were selected. - Positive control:
- not applicable
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least twice daily. Animals showing pain, distress or discomfort, which was considered not transient in nature or was likely to become more severe, were sacrificed for humane reasons based on OECD guidance document on humane endpoints (ENV/JM/MONO/ 2000/7). The circumstance of any death was recorded in detail.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily, detailed clinical observations were conducted for all animals. Observations were started after dosing at no specific time point, but within a similar time period for the respective animals throughout the study. Once prior to start of treatment and at weekly intervals during the treatment period this was also performed outside the home cage in a standard arena. Arena observations were not performed when the animals were mating, or housed individually. The time of onset, grade and duration of any observed sign was recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: Males and females were weighed on the first day of exposure and weekly
thereafter. Mated females were weighed on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum, and during lactation on
Days 1 and 4.
FOOD CONSUMPTION: Yes.
Weekly, for males and females. Food consumption was not recorded during the mating period. Food
consumption of mated females was measured on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum and on Days 1 and 4
of lactation.
FOOD EFFICIENCY: Yes. (average food consumption [per animal per day]/average body weight per cage)x1000
WATER CONSUMPTION : No.
Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was
suspected.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
Blood samples were drawn from the retro-orbital sinus and collected into tubes (Greiner Bio-One, Bad Haller,
Austria) prepared with EDTA for haematological parameters (0.5 mL) and with citrate for clotting tests (0.45 mL).
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.00
and 10.30 a.m
- Anaesthetic used for blood collection: Yes (iso-flurane)
- Animals fasted: Yes (with a maximum of 20 hours). Water was provided.
- How many animals: 5 animals/sex/group
- Parameters checked were: according to OECD 422 (1996)
CLINICAL CHEMISTRY: Yes
Blood samples were drawn from the retro-orbital sinus and collected into tubes (Greiner Bio-One, Bad Haller,
Austria) prepared with Li-heparin treated tubes for clinical biochemistry parameters (0.5 mL). An additional blood
sample (0.25 mL) was collected into untreated tubes for determination of bile acids.
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.00
and 10.30 a.m
- Animals fasted: Yes (with a maximum of 20 hours). Water was provided.
- How many animals: 5 animals/sex/group
- Parameters checked in table were: according to OECD 422 (1996); except alkaline phosphatase was measured instead of sorbitol dehydrogenase
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: The selected males were tested during Week 4 of treatment and the selected
females were tested during lactation (all before blood sampling).
- Dose groups that were examined: all (5 animals/sex/group)
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex, grip strength and motor activity
test (recording period: 1-hour for individual animals, using a computerised monitoring system. During the motor activity
test, males were caged individually and females were caged with their pups.
GROSS PATHOLOGY: Yes
All animals were fasted overnight (with a maximum of 20 hours) prior to planned necropsy, but water was
provided. Animals surviving to scheduled necropsy and all moribund animals were deeply anaesthetised using
isoflurane vapor and subsequently exsanguinated.
Necropsy was conducted on the following days:
Females which delivered: lactation Days 5-67
Females which failed to deliver (nos. 46, 66 and 77): post-coitum Days 26-27 (females with evidence of mating)
Males: following completion of the mating period (a minimum of 28 days of dose administration).
All animals were subjected to macroscopic examination of the cranial, thoracic and abdominal tissues and organs,
with special attention being paid to the reproductive organs. Descriptions of all macroscopic abnormalities were
recorded. The number of former implantation sites and corpora lutea were recorded for all paired females.
- Selected 5 animals/sex/group and all animals that were killed in extremis : according to OECD 422 (1996)
- All remaining animals and females which failed to deliver: according to OECD 422 (1996)
ORGAN WEIGHTS
The following organ weights and terminal body weight were recorded from the following animals on the scheduled
day of necropsy:
- Selected 5 animals/sex/group: according to OECD 422 (1996)
- All remaining males: testes and epididymides
HISTOPATHOLOGY: Yes, according to OECD 422 (1996). - Oestrous cyclicity (parental animals):
- not examined
- Sperm parameters (parental animals):
- Staging of spermatogenesis was examined for the selected 5 males of the control and high dose group, and all males suspected to be infertile.
- Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
- Mortality: The numbers of live and dead pups on Day 1 of lactation and daily thereafter were determined.
- Clinical signs: At least once daily, detailed clinical observations were made in all animals.
- Body weights: Live pups were weighed on Days 1 and 4 of lactation.
- Sex: Sex was determined for all pups on Days 1 and 4 of lactation.
GROSS EXAMINATION OF DEAD PUPS
Yes, if possible, defects or cause of death were evaluated. The stomach was examined for the presence of milk. - Postmortem examinations (parental animals):
- see at "observations and examinations"
- Postmortem examinations (offspring):
- see at "litter observations"
- Statistics:
- The following statistical methods were used to analyze the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-to-one rank test) was applied if the data could not be assumed to follow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
The following additional methods of statistical analysis were used:
Motor activity data was subjected to the Kruskal-Wallis nonparametric ANOVA test to determine intergroup differences followed by the Wilcoxon test to compare the treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. - Reproductive indices:
- For each group, the following calculations were performed:
- Mating index: Number of females mated/Number of females paired x 100
- Fertility index: Number of pregnant females/Number of females paired x 100
- Conception index: Number of pregnant females/Number of females mated x 100
- Gestation index: Number of females bearing live pups/Number of pregnant females x 100
- Duration of gestation: Number of days between confirmation of mating and the beginning of parturition - Offspring viability indices:
- - Percentage live males at First Litter Check: Number of live male pups at First Litter Check/Number of live pups at First Litter Check x 100
- Percentage live females at First Litter Check: Number of live female pups at First Litter Check/Number of live pups at First Litter Check x 100
- Percentage of postnatal loss Days 0-4 of lactation: Number of dead pups on Day 4 of lactation/Number of live pups at First Litter Check x 100
- Viability index: Number of live pups on Day 4 of lactation / Number of pups born alive x 100 - Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- parental
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: increased incidence and severity of macrophage foci at 300 and 1000 mg/kg bw/d with concurrent increased incidence and severity of necrosis of the mesenteric lymph node at 1000 mg/kg bw/d
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed up to the highest dose tested
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed up to the highest dose tested
- Reproductive effects observed:
- no
- Conclusions:
- The NOAEL for parental toxicity is set at 100 mg/kg bw/d based on an increased incidence and severity of macrophage foci at 300 and 1000 mg/kg bw/d with concurrent increased incidence and severity of necrosis of the mesenteric lymph node at 1000 mg/kg bw/d. The NOAEL for reproduction toxicity was determined to be 1000 mg/kg bw/d in the absence of effects observed.
- Executive summary:
In an OECD 422 study rats were administered 0, 100, 300 or 1000 mg/kg bw/d of HK 128 by gavage. Parameters checked were according to OECD 422.
No effects were observed with relation to body weight, food consumption, neurobehavioural examination, haematology and macroscopy. One female at 1000 mg/kg bw/d was killed in extremis on day 8 of treatment having severe body weight loss, stomach distended with gas, with a dark red focus on the stomach glandular mucosa, both adrenal glands enlarged, reduced size of the thymus, necrosis of the caecum villi and of liver hepatocytes along with lymphoid atrophy. At 1000 mg/kg bw/d significantly higher alanine aminotransferase (ALAT) and inorganic phosphate were seen for males along with significantly lower total protein and albumin. Females at this dose level had significantly higher cholesterol values compared to controls. In the absence of effects on other endpoints indicating altered liver function, these were not considered to be biologically significant. At 1000 mg/kg bw/d absolute and relative liver weight was increased in females, while relative liver weights were higher in males. Males at this dose level had also lower absolute and relative seminal vesicle weights and a higher relative adrenal weight. In absence of histopathological effects on these organs these effects were not considered to be toxicologically relevant. At 300 and 1000 mg/kg bw/d an increased incidence and severity of macrophage foci in the mesenteric lymph node was noted with concurrent increased incidence and severity of necrosis of the mesenteric lymph node at 1000 mg/kg bw/d.
Based on the effects on the mesenteric lymph node, the NOAEL is set at 100 mg/kg bw/d for parental toxicity. As no effects on reproduction toxicity were observed the NOAEL was established to be 1000 mg/kg bw/d.
Reference
One female at 1000 mg/kg was euthanized in extremis on Day 8 of the treatment period. She was noted with lethargy, hunched posture, labored respiration, piloerection, lean appearance, ptosis, chromodacryorrhoea, and hypothermia; she also had severe body weight loss (of 22%, on Day 8 of the pre-mating period) prior to euthanasia. This female was found with her stomach distended with gas, with a dark red focus on the stomach glandular mucosa, both adrenal glands enlarged, reduced size of the thymus and was found to be emaciated at the macroscopic examination. At the microscopic examination, necrosis of the caecum villi and of liver hepatocytes were seen, along with lymphoid atrophy. A relationship to treatment could not be excluded.
CLINICAL SIGNS:
There were no clinical signs of toxicity noted during the observation period for surviving animals.
Salivation was noted for all males and all surviving females at 1000 mg/kg through most of the treatment period, beginning around Day 10 of treatment (or slightly later). Salivation was also noted for all males and 6 of the 10 females at 300 mg/kg. Due to its time of occurrence (after dosing), salivation was likely due to a physiological response attributable to the taste or possible irritancy of the test substance, was not considered to be a sign of toxicity.
NEUROBEHAVIOUR:
Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all animals. The variation in motor activity did not indicate a relation with treatment. All groups showed a similar habituation profile with very high activity in the first interval that decreased over the duration of the test period.
BODY WEIGHT:
No toxicologically relevant changes in body weights and body weight gain were noted.
Females at 1000 mg/kg had significantly higher body weight gain on Day 1 of the mating period. However, the difference from controls was only slight, and was not considered to be attributable to treatment with HK 128.
FOOD CONSUMPTION:
No toxicologically relevant changes in food consumption before or after allowance for body weight were noted up to 1000 mg/kg.
Relative food consumption was slightly higher for males and females at 1000 mg/kg over Days 1-8 of the mating period and Days 8-15 of the pre-mating period, respectively. This was not considered toxicologically relevant as the difference from controls was slight, values remained within the range considered normal for animals of this age and strain, and a reduction in food consumption would be more likely to be seen if the difference from controls was due to toxicity.
HAEMATOLOGY:
No toxicologically relevant changes occurred in haematological parameters of treated rats.
The significant increase in reticulocytes seen for females at 1000 mg/kg was attributable to a high value obtained for female no. 71, and was not indicative of a treatment-related effect.
There was a trend towards higher neutrophils and lower lymphocytes (not statistically significant) for males at 1000 mg/kg. This shift in type of white blood cells was considered to be a secondary non-specific response to stress and was not toxicologically relevant. The mean neutrophils were higher and mean lymphocytes lower for controls than for all treated females. However, high lymphocytes with concomitant low neutrophils were also noted for a control female (no. 49), which contributed to these mean values and high standard deviation seen for control females in these two parameters. When re-calculated without her data, control means for neutrophils and lymphocytes were the same for control females as for the treated groups.
CLINICAL BIOCHEMISTRY:
There were no toxicologically relevant effects on clinical biochemistry parameters up to 1000 mg/kg.
At 1000 mg/kg significantly higher alanine aminotransferase (ALAT) and inorganic phosphate were seen for males along with significantly lower total protein and albumin. Females at this dose level had significantly higher cholesterol values compared to controls. In the absence of effects on other endpoints indicating altered liver function, these were not considered to be biologically significant.
The significantly lower total protein and albumin seen for females at 100 mg/kg were likely due to slightly low values obtained for two females. Along with the lower potassium seen for males at 100 mg/kg, these changes occurred in the absence of a treatment-related distribution and were not considered to be toxicologically relevant.
MACROSCOPIC EXAMINATION:
No treatment-related effects were noted at macroscopy.
Incidental findings seen for control and/or treated animals included pelvic dilation of the kidneys, reddish or dark red foci on the thymus or stomach glandular mucosa, reddish, red-brown, dark red, or tan discoloration of the thymus, clitoral glands and/or mandibular lymph nodes, yellowish, soft nodule on the head of the right epididymis, and scabbing on the cheek. These findings occurred for control and treated animals without a treatment related distribution and at the incidence observed, were not considered to be treatment related.
ORGAN WEIGHTS:
At 1000 mg/kg females had higher absolute and relative liver weights while higher relative liver weights were noted for males. Additionally, males at this dose level had higher relative adrenal weights and lower absolute and relative seminal vesicle weights. These differences in organ weights and organ to body weight ratios were not accompanied by any treatment-related changes noted at the histopathological examination. As such these effects were considered treatment related but not toxicologically relevant.
MICROSCOPIG EXAMINATION:
Microscopic treatment-related findings were present in males and females in the mesenteric lymph node including necrosis that was present in 3/5 males (1 minimal, 2 slight) and 2/5 females (1 minimal, 1 slight) treated at 1000 mg/kg (Group 4). Additionally, macrophage foci were present at an increased incidence and severity in 5/5 male (3 slight, 2 moderate) and 5/5 female (2 slight, 3 moderate) rats treated at 300 mg/kg (Group 3) and in 5/5 male (3 slight, 2 moderate) and 5/5 female (1 slight 4 moderate) rats treated at 1000 mg/kg compared to 2/5 male (2 minimal) and 1/5 female (minimal) controls (Group 1) and 3/5 female (3 minimal) 100 mg/kg (Group 2) treated rats. A minimal degree of macrophage foci is considered to be within the normal limits.
REPRODUCTIVE DATA:
No toxicologically relevant effects on reproductive parameters were noted. There were 9, 10, 9 and 8 pregnant females in the control, 100, 300 and 1000 mg/kg groups, respectively. There were no treatment related effects on the mating, fertility and conception indices, precoital time, number of corpora lutea or implantation sites. The number of implantation sites at 300 mg/kg were significantly lower than for females of the control group. In the absence of a treatment related distribution and any relevant effects on other reproductive parameters, this was not considered to be treatment-related.
The assessment of the integrity of the spermatogenetic cycle did not provide any evidence of impaired spermatogenesis and there were no morphological findings in the reproductive organs of either sex which could be attributed to the test item.
GESTATION:
The gestation index and duration of gestation were unaffected by treatment up to 1000 mg/kg bw/d.
PARTURITION/MATERNAL CARE:
No signs of difficult or prolonged parturition were noted among the pregnant females.
Examination of cage debris of pregnant females revealed no signs of abortion or premature birth. No deficiencies in maternal care were observed.
Number of dead and living pups at first litter check, postnatal loss, viability index and sex ratio were unaffected by treatment, and clinical signs, body weight and external macroscopy did not reveal treatment-related findings.
MORTALITY PUPS
One pup of the control group and two, one and one pups of the 100, 300 and 1000 mg/kg groups were found dead or went missing during the first days of lactation. Missing pups were most likely cannibalized. No toxicological relevance was attributed to these dead/missing pups since the mortality incidence did not show a dose-related trend and remained within the range considered normal for pups of this age.
CLINICAL SIGNS PUPS
Pale appearance was noted for one pup at first litter check from one litter at 100 mg/kg. This was the only observation noted for any pup. The nature and incidence of this remained within the range considered normal for pups of this age, and were therefore not considered to be toxicologically relevant.
BODY WEIGHT PUPS
Body weights were significantly higher for pups of both sexes at 300 mg/kg on lactation Days 1 and 4. The increased body weights were, in part, attributable to very high weights obtained from two litters with 8 and 6 pups, respectively. The relatively low number of pups in these litters contributed to the higher weights as more milk was available for each individual pup than in larger litters.
MACROSCOPY PUPS
No effects observed.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- adequate
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In an OECD 422 test with the registered substance, toxicity occurred only in the parental adult animals at doses of 300 and 1000 mg/kg bw/d. There was no reproduction toxicity observed up to the highest dose level tested (1000 mg/kg bw/d), when the following parameters were examined: standard indices (mating, fertility and conception), precoital time, number of corpora lutea and number of implantation sites. Under the conditions of this assay, the test material was NOT found to result in reproductive toxicity at doses up to 1000 mg/kg bw/d.
Short description of key information:
No reproduction toxicity was observed up to the highest dose level tested (1000 mg/kg bw/d).
Justification for selection of Effect on fertility via oral route:
Conclusion of guideline study performed under GLP. Further support is provided by provided an absence of adverse effects in the reproductive organs and function during repeated dose toxicity testing. The conditions of Regulation (EC) No.1907/2006, Annex IX, 8.7.3, Column 1, are not met, and so the additional testing is not indicated.
Effects on developmental toxicity
Description of key information
No developmental toxicity was observed up to the highest dose level tested (1000 mg/kg bw/d). A valid computer model predicts that the substance is not a developmental reprotoxicant.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March - June 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 422, Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: US EPA, OPPTS870.3650, Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
- Deviations:
- no
- Principles of method if other than guideline:
- In addition, the procedures described in this report essentially conform to the following guidelines.
1. The United States EPA Health Effects Test Guidelines, OPPTS 870.3550, Reproduction/Developmental Toxicity Screening Test, July 2000.
2. OECD Guidelines for Testing of Chemicals, Guideline 421, Reproduction/Developmental Toxicity Screening Test, July 1995.
3. Commission regulation (EC) No 440/2008 Part B: Methods for the Determination of Toxicity and other Health Effects; B.7: "Repeated Dose (28 days) Toxicity (oral)". Official Journal of the European Union No. L142, May 2008.
4. OECD Guidelines for Testing of Chemicals, Guideline 407, Repeated Dose 28-day Oral Toxicity Study in Rodents, October 2008.
5. The United States EPA Health Effects Test Guidelines, OPPTS 870.3050, Repeated dose 28-day oral toxicity study in rodents, July 2000. - GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approx. 11 weeks
- Weight at study initiation: within ± 20% of the sex mean (males:280-309 grams, females: 191-219 grams)
- Fasting period before study: no
- Housing: groups of 5 animals/sex/cage during pre-mating and post-mating (males), females were individually housed post-mating and during lactation; Macrolon plastic cages with sterilized sawdust as bedding material and paper as cage-enrichment/nesting material
- Diet: free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany)
- Water: free access to tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18.7-20.9
- Humidity (%): 38-95; temporary deviations from the minimum and daily mean relative humidity occurred. Laboratory historical data do not indicate an effect of the deviations.
- Air changes (per hr): approx. 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: 01 May - 22 June 2012 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- Method of formulation: Formulations (w/w) were prepared daily within 6 hours prior to dosing and were homogenized to a visually acceptable level. No correction was made for the purity of the test substance. Adjustment was made for specific gravity (1.036) of the vehicle. The test substance was warmed to facilitate mixing (max temperature= 82.7°C, for a maximum of 58 minutes).
Storage conditions of formulations: at ambient temperature
Justification for use and choice of vehicle (if other than water): based on trial formulations performed at WIL Research Europe
Dose volume: 5 mL/kg body weight. Actual dose volumes were calculated according to the latest body weight
Method of gavage: using a plastic feeding tube. Formulations were placed on a magnetic stirrer during dosing. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Chemical analysis were conducted twice during the main study (Days 2 and 14 of the treatment phase; 02 and 14 May 2012 respectively), according to a validated method (Project 498662). Samples of formulations were analyzed for homogeneity (highest and lowest concentration) and accuracy of preparation (all concentrations). Stability in the vehicle over 6 hours at room temperature was also determined (highest and lowest concentration).
The concentrations analysed in the formulations of Group 2, Group 3 and Group 4 were in agreement with target concentrations (i.e. mean accuracies between 85% and 115%).
A small response at the retention time of the test substance was observed in the chromatograms of the Group 1 formulation prepared for use on Day 14. The maximum contribution based on area to the other samples was 3.3%. A small response was also seen in the blank injection sample analyzed. In the formulations of Group 1 of Day 2, no test substance was detected.
The formulations of Group 2 and Group 4 were homogeneous (i.e. coefficient of variation ≤ 10%).
Formulations at the entire range were stable when stored at room temperature under normal laboratory light conditions for at least 6 hours (relative difference before and after storage was maximally 10%). - Details on mating procedure:
- Following a minimum of 14 days of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating occurred, the males and females were separated.
- Duration of treatment / exposure:
- Females were exposed for 42-52 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation. One female from Group 1, 2 and 4 each were not dosed during littering.
- Frequency of treatment:
- Once daily for 7 days per week, approximately the same time each day with a maximum of 6 hours difference between the earliest and latest dose. Animals were dosed up to the day prior to scheduled necropsy.
- Duration of test:
- 42-52 days
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Parturition:
The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes, placentas cleaned up, nest built up and/or feeding of pups started). Females that were littering were left undisturbed.
Identification of pups:
On Day 1 of lactation, all pups were randomized per litter and individually identified by means of subcutaneous injection of Indian ink.
Selection of animals for selected measurements:
5 animals/sex/group were randomly selected at allocation for functional observations, locomotor activity, clinical pathology, macroscopic examination (full list), organ weights (full list) and histopathology. Only females with live offspring were selected. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least twice daily. Animals showing pain, distress or discomfort, which was considered not transient in nature or was likely to become more severe, were sacrificed for humane reasons based on OECD guidance document on humane endpoints (ENV/JM/MONO/ 2000/7). The circumstance of any death was recorded in detail.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily, detailed clinical observations were conducted for all animals. Observations were started after dosing at no specific time point, but within a similar time period for the respective animals throughout the study. Once prior to start of treatment and at weekly intervals during the treatment period this was also performed outside the home cage in a standard arena. Arena observations were not performed when the animals were mating, or housed individually. The time of onset, grade and duration of any observed sign was recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: Mated females were weighed on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum, and during lactation on
Days 1 and 4.
FOOD CONSUMPTION: Yes.
Food consumption of mated females was measured on Days 0, 4, 7, 11, 14, 17 and 20 post-coitum and on Days 1 and 4 of lactation.
FOOD EFFICIENCY: Yes. (average food consumption [per animal per day]/average body weight per cage)x1000
WATER CONSUMPTION : No.
Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was
suspected.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
Blood samples were drawn from the retro-orbital sinus and collected into tubes (Greiner Bio-One, Bad Haller,
Austria) prepared with EDTA for haematological parameters (0.5 mL) and with citrate for clotting tests (0.45 mL).
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.00
and 10.30 a.m
- Anaesthetic used for blood collection: Yes (iso-flurane)
- Animals fasted: Yes (with a maximum of 20 hours). Water was provided.
- How many animals: 5 animals/group
- Parameters checked were: according to OECD 422 (1996)
CLINICAL CHEMISTRY: Yes
Blood samples were drawn from the retro-orbital sinus and collected into tubes (Greiner Bio-One, Bad Haller,
Austria) prepared with Li-heparin treated tubes for clinical biochemistry parameters (0.5 mL). An additional blood
sample (0.25 mL) was collected into untreated tubes for determination of bile acids.
- Time schedule for collection of blood: immediately prior to scheduled post mortem examination, between 7.00
and 10.30 a.m
- Animals fasted: Yes (with a maximum of 20 hours). Water was provided.
- How many animals: 5 animals/group
- Parameters checked in table were: according to OECD 422 (1996); except alkaline phosphatase was measured instead of sorbitol dehydrogenase
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: The selected females were tested during lactation (all before blood sampling).
- Dose groups that were examined: all (5 animals/group)
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex, grip strength and motor activity
test (recording period: 1-hour for individual animals, using a computerised monitoring system. During the motor activity
test, males were caged individually and females were caged with their pups.
GROSS PATHOLOGY: Yes
All animals were fasted overnight (with a maximum of 20 hours) prior to planned necropsy, but water was
provided. Animals surviving to scheduled necropsy and all moribund animals were deeply anaesthetised using
isoflurane vapor and subsequently exsanguinated.
Necropsy was conducted on the following days:
Females which delivered: lactation Days 5-67
Females which failed to deliver: post-coitum Days 26-27 (females with evidence of mating)
All animals were subjected to macroscopic examination of the cranial, thoracic and abdominal tissues and organs,
with special attention being paid to the reproductive organs. Descriptions of all macroscopic abnormalities were
recorded. The number of former implantation sites and corpora lutea were recorded for all paired females.
- Selected 5 animals/group and all animals that were killed in extremis : according to OECD 422 (1996)
- All remaining animals and females which failed to deliver: according to OECD 422 (1996)
ORGAN WEIGHTS: Yes
The following organ weights and terminal body weight were recorded from the following animals on the scheduled
day of necropsy:
- Selected 5 animals/group: according to OECD 422 (1996)
HISTOPATHOLOGY: Yes, according to OECD 422 (1996). - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: No
- Number of late resorptions: No - Fetal examinations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
- Mortality: The numbers of live and dead pups on Day 1 of lactation and daily thereafter were determined.
- Clinical signs: At least once daily, detailed clinical observations were made in all animals.
- Body weights: Live pups were weighed on Days 1 and 4 of lactation.
- Sex: Sex was determined for all pups on Days 1 and 4 of lactation.
GROSS EXAMINATION OF DEAD PUPS
Yes, if possible, defects or cause of death were evaluated. The stomach was examined for the presence of milk. - Statistics:
- The following statistical methods were used to analyze the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test (many-to-one rank test) was applied if the data could not be assumed to follow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
The following additional methods of statistical analysis were used:
Motor activity data was subjected to the Kruskal-Wallis nonparametric ANOVA test to determine intergroup differences followed by the Wilcoxon test to compare the treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. - Indices:
- Reproductive indices; For each group, the following calculations were performed:
- Mating index: Number of females mated/Number of females paired x 100
- Fertility index: Number of pregnant females/Number of females paired x 100
- Conception index: Number of pregnant females/Number of females mated x 100
- Gestation index: Number of females bearing live pups/Number of pregnant females x 100
- Duration of gestation: Number of days between confirmation of mating and the beginning of parturition
Offspring indices:
- Percentage live males at First Litter Check: Number of live male pups at First Litter Check/Number of live pups at First Litter Check x 100
- Percentage live females at First Litter Check: Number of live female pups at First Litter Check/Number of live pups at First Litter Check x 100
- Percentage of postnatal loss Days 0-4 of lactation: Number of dead pups on Day 4 of lactation/Number of live pups at First Litter Check x 100
- Viability index: Number of live pups on Day 4 of lactation / Number of pups born alive x 100 - Historical control data:
- no data
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
MORTALITY:
One female at 1000 mg/kg was euthanized in extremis on Day 8 of the treatment period. She was noted with lethargy, hunched posture, labored respiration, piloerection, lean appearance, ptosis, chromodacryorrhoea, and hypothermia; she also had severe body weight loss (of 22%, on Day 8 of the pre-mating period) prior to euthanasia. This female was found with her stomach distended with gas, with a dark red focus on the stomach glandular mucosa, both adrenal glands enlarged, reduced size of the thymus and was found to be emaciated at the macroscopic examination. At the microscopic examination, necrosis of the caecum villi and of liver hepatocytes were seen, along with lymphoid atrophy. A relationship to treatment could not be excluded.
CLINICAL SIGNS:
There were no clinical signs of toxicity noted during the observation period for surviving animals.
Salivation was noted for all surviving females at 1000 mg/kg through most of the treatment period, beginning around Day 10 of treatment (or slightly later). Salivation was also noted for 6 of the 10 females at 300 mg/kg. Due to its time of occurrence (after dosing), salivation was likely due to a physiological response attributable to the taste or possible irritancy of the test substance, was not considered to be a sign of toxicity.
NEUROBEHAVIOUR:
Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all animals. The variation in motor activity did not indicate a relation with treatment. All groups showed a similar habituation profile with very high activity in the first interval that decreased over the duration of the test period.
BODY WEIGHT:
No toxicologically relevant changes in body weights and body weight gain were noted.
Females at 1000 mg/kg had significantly higher body weight gain on Day 1 of the mating period. However, the difference from controls was only slight, and was not considered to be attributable to treatment with HK 128.
FOOD CONSUMPTION:
No toxicologically relevant changes in food consumption before or after allowance for body weight were noted up to 1000 mg/kg.
Relative food consumption was slightly higher for males and females at 1000 mg/kg over Days 1-8 of the mating period and Days 8-15 of the pre-mating period, respectively. This was not considered toxicologically relevant as the difference from controls was slight, values remained within the range considered normal for animals of this age and strain, and a reduction in food consumption would be more likely to be seen if the difference from controls was due to toxicity.
HAEMATOLOGY:
No toxicologically relevant changes occurred in haematological parameters of treated rats.
The significant increase in reticulocytes seen for females at 1000 mg/kg was attributable to a high value obtained for one female, and was not indicative of a treatment-related effect.
The mean neutrophils were higher and mean lymphocytes lower for controls than for all treated females. However, high lymphocytes with concomitant low neutrophils were also noted for a control female, which contributed to these mean values and high standard deviation seen for control females in these two parameters. When re-calculated without her data, control means for neutrophils and lymphocytes were the same for control females as for the treated groups.
CLINICAL BIOCHEMISTRY:
There were no toxicologically relevant effects on clinical biochemistry parameters up to 1000 mg/kg.
Females at 1000 mg/kg had significantly higher cholesterol values compared to controls. In the absence of effects on other endpoints indicating altered liver function, these were not considered to be biologically significant.
The significantly lower total protein and albumin seen for females at 100 mg/kg were likely due to slightly low values obtained for two female. These changes occurred in the absence of a treatment-related distribution and were not considered to be toxicologically relevant.
MACROSCOPIC EXAMINATION:
No treatment-related effects were noted at macroscopy.
Incidental findings seen for control and/or treated animals included pelvic dilation of the kidneys, reddish or dark red foci on the thymus or stomach glandular mucosa, reddish, red-brown, dark red, or tan discoloration of the thymus, clitoral glands and/or mandibular lymph nodes, yellowish, soft nodule on the head of the right epididymis, and scabbing on the cheek. These findings occurred for control and treated animals without a treatment related distribution and at the incidence observed, were not considered to be treatment related.
ORGAN WEIGHTS:
At 1000 mg/kg females had higher absolute and relative liver weights while higher relative liver weights were noted for males. These differences in organ weights and organ to body weight ratios were not accompanied by any treatment-related changes noted at the histopathological examination. As such these effects were considered treatment related but not toxicologically relevant.
MICROSCOPIG EXAMINATION:
Microscopic treatment-related findings were present in females in the mesenteric lymph node including necrosis that was present in 2/5 females (1 minimal, 1 slight) treated at 1000 mg/kg (Group 4). Additionally, macrophage foci were present at an increased incidence and severity in 5/5 female (2 slight, 3 moderate) rats treated at 300 mg/kg (Group 3) and in 5/5 female (1 slight 4 moderate) rats treated at 1000 mg/kg compared to 1/5 female (minimal) controls (Group 1) and 3/5 female (3 minimal) 100 mg/kg (Group 2) treated rats. A minimal degree of macrophage foci is considered to be within the normal limits.
REPRODUCTIVE DATA:
No toxicologically relevant effects on reproductive parameters were noted. There were 9, 10, 9 and 8 pregnant females in the control, 100, 300 and 1000 mg/kg groups, respectively. There were no treatment related effects on the mating, fertility and conception indices, precoital time, number of corpora lutea or implantation sites. The number of implantation sites at 300 mg/kg were significantly lower than for females of the control group. In the absence of a treatment related distribution and any relevant effects on other reproductive parameters, this was not considered to be treatment-related.
GESTATION:
The gestation index and duration of gestation were unaffected by treatment up to 1000 mg/kg bw/d.
PARTURITION/MATERNAL CARE:
No signs of difficult or prolonged parturition were noted among the pregnant females.
Examination of cage debris of pregnant females revealed no signs of abortion or premature birth. No deficiencies in maternal care were observed. - Dose descriptor:
- NOAEL
- Effect level:
- ca. 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- clinical signs
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
EARLY POSTNATAL PUP DEVELOPMENT
Number of dead and living pups at first litter check, postnatal loss, viability index and sex ratio were unaffected by treatment, and clinical signs, body weight and external macroscopy did not reveal treatment-related findings.
MORTALITY PUPS
One pup of the control group and two, one and one pups of the 100, 300 and 1000 mg/kg groups were found dead or went missing during the first days of lactation. Missing pups were most likely cannibalized. No toxicological relevance was attributed to these dead/missing pups since the mortality incidence did not show a dose-related trend and remained within the range considered normal for pups of this age.
CLINICAL SIGNS PUPS
Pale appearance was noted for one pup at first litter check from one litter at 100 mg/kg. This was the only observation noted for any pup. The nature and incidence of this remained within the range considered normal for pups of this age, and were therefore not considered to be toxicologically relevant.
BODY WEIGHT PUPS
Body weights were significantly higher for pups of both sexes at 300 mg/kg on lactation Days 1 and 4. The increased body weights were, in part, attributable to very high weights obtained from two litters with 8 and 6 pups, respectively. The relatively low number of pups in these litters contributed to the higher weights as more milk was available for each individual pup than in larger litters.
MACROSCOPY PUPS
No effects observed. - Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed up to the highest dose tested
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- The NOAEL for parental toxicity is set at 100 mg/kg bw/d based on an increased incidence and severity of macrophage foci at 300 and 1000 mg/kg bw/d with concurrent increased incidence and severity of necrosis of the mesenteric lymph node at 1000 mg/kg bw/d. The NOAEL for developmental toxicity was determined to be 1000 mg/kg bw/d in the absence of effects observed.
- Executive summary:
In an OECD 422 study rats were administered 0, 100, 300 or 1000 mg/kg bw/d of HK 128 by gavage. Parameters checked were according to OECD 422.
No effects were observed with relation to body weight, food consumption, neurobehavioural examination, haematology and macroscopy. One female at 1000 mg/kg bw/d was killed in extremis on day 8 of treatment having severe body weight loss, stomach distended with gas, with a dark red focus on the stomach glandular mucosa, both adrenal glands enlarged, reduced size of the thymus, necrosis of the caecum villi and of liver hepatocytes along with lymphoid atrophy. At 1000 mg/kg bw/d females had significantly higher cholesterol values compared to controls. In the absence of effects on other endpoints indicating altered liver function, these were not considered to be biologically significant. At 1000 mg/kg bw/d absolute and relative liver weight was increased in females. In absence of histopathological effects on these organs these effects were not considered to be toxicologically relevant. At 300 and 1000 mg/kg bw/d an increased incidence and severity of macrophage foci in the mesenteric lymph node was noted with concurrent increased incidence and severity of necrosis of the mesenteric lymph node at 1000 mg/kg bw/d.
Based on the effects on the mesenteric lymph node, the NOAEL is set at 100 mg/kg bw/d for parental toxicity. As no effects on developmental toxicity were observed the NOAEL was established to be 1000 mg/kg bw/d.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- adequate
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In an OECD 422 test with the registered substance, toxicity occurred only in the parental adult animals at doses of 300 and 1000 mg/kg bw/d. There was no developmental toxicity observed up to the highest dose level tested (1000 mg/kg bw/d), when the following parameters were examined: gestation index, duration of gestation, parturition, maternal care (including lactation) and early postnatal pup development (mortality, clinical signs, body weight and macroscopy). Under the conditions of this assay, the test material was NOT found to result in developmental toxicity at doses up to 1000 mg/kg bw/d. Further support is provided by modeling the developmental toxicity of the structure with a valid SAR program, the results of which indicate that the substance is not associated with adverse developmental effects during reproduction.
Justification for selection of Effect on developmental toxicity: via oral route:
Conclusion of guideline study performed under GLP. Further support is provided by modeling the developmental toxicity of the structure with a valid SAR program, the results of which indicate that the substance is not associated with adverse developmental effects during reproduction.
Justification for classification or non-classification
Reproductive and developmental toxicity was assessed in rats given the registered substance in a 28 -day OECD 421/422 toxicity assay. There was no evidence of reproductive or developmental toxicity at doses up to 1000 mg/kg bw/d, even in the presence of maternal (adult) toxicity. Further assessment of Structure-Activity Relationship modeling for reproductive and developmental toxicity indicates that the substance is not associated with adverse effects during reproduction. The data do not meet any criteria for classification for reproductive or developmental toxicity.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.